^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

FCRL4 (Fc Receptor Like 4)

i
Other names: FCRL4, Fc Receptor Like 4, FCRH4, IRTA1, CD307d, IGFP2, Immune Receptor Translocation-Associated Protein 1, Fc Receptor-Like Protein 4, IFGP Family Protein 2, Fc Receptor Homolog 4, FcR-Like Protein 4, HIFGP2, Immunoglobulin Superfamily Receptor Translocation Associated 1, Immunoglobulin Superfamily Fc Receptor, Gp42, Fc Receptor-Like 4, CD307d Antigen, IFGP2, FcRL4, FcRH4
Associations
Trials
2ms
CD20+FCRL4+ B Cells Activate CD8+ T Cells via MHC-I Restriction in Nasopharyngeal Carcinoma Anti-Tumor Immunity. (PubMed, Adv Sci (Weinh))
Ultimately, this process mediates the cytotoxicity of CD8+ T cells against tumor cells both in vitro and in vivo. Notably, we found a positive correlation between the infiltration level of CD20+FCRL4+ B cells and the expression of PD-1, as well as the response to anti-PD-1 therapy or gemcitabine plus cisplatin combined with anti-PD-1 therapy in NPC.Overall, our study elucidates the potential anti-tumor mechanisms of CD20+FCRL4+ B cells and provides insights into their role in immunotherapy for NPC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • FCRL4 (Fc Receptor Like 4)
|
cisplatin • gemcitabine
2ms
Mapping the B-cell axis in Sjögren's disease: repertoire, microenvironment, and potential routes to precision treatment. (PubMed, Curr Opin Immunol)
Chronic B-cell receptor signaling and clonal evolution provide a bridge to lymphoma risk. In this review, we outline how these converging pathways define molecular endotypes and propose a precision framework linking them to targeted therapy in SjD.
Review • Journal
|
CXCL13 (Chemokine (C-X-C motif) ligand 13) • IL21 (Interleukin 21) • TLR7 (Toll Like Receptor 7) • FCRL4 (Fc Receptor Like 4) • SLC2A1 (Solute Carrier Family 2 Member 1)
5ms
FCRLs and atypical transcriptional pattern in tumor infiltrating B cells from lung and renal cancer. (PubMed, Front Immunol)
Additionally, in renal cancer, high IGHA1/IGHG1 ratios were linked to worse survival. These findings suggest that the IgA/IgG ratio in tumors reflects not only the TME cytokine environment, but also functional differences in B cell populations, providing insights into their diverse roles in tumor progression.
Journal • PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • CD20 (Membrane Spanning 4-Domains A1) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • IFNA1 (Interferon Alpha 1) • IGHG1 (Immunoglobulin Heavy Constant Gamma 1) • IL5 (Interleukin 5) • FCRL4 (Fc Receptor Like 4) • RUNX2 (RUNX Family Transcription Factor 2)
|
KRAS wild-type • RAS wild-type
8ms
Mature tertiary lymphoid structures linked to HPV status and anti-PD-1 based chemoimmunotherapy response in head and neck squamous cell carcinoma. (PubMed, Oncoimmunology)
Notably, neoadjuvant chemoimmunotherapy promoted mature TLS formation. These results suggest that TLS maturity correlates with HPV status and response to anti-PD-1-based chemoimmunotherapy, providing insights for potential therapeutic strategies in HNSCC.
Journal
|
CD8 (cluster of differentiation 8) • FCRL4 (Fc Receptor Like 4)
1year
Identification and analysis of a cell communication prognostic signature for oral squamous cell carcinoma at bulk and single-cell levels. (PubMed, J Cell Mol Med)
We comprehensively interpreted the immune microenvironment pattern of OSCC based on the single-cell sequencing data and bulk sequencing data analysis. A robust immune feature-based prognostic model was developed for the precise treatment and prognosis evaluation of OSCC.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • FCRL4 (Fc Receptor Like 4)
|
IL17RB expression
over1year
Prognostic value of atypical B cells in breast cancer. (PubMed, Trends Cancer)
Recent findings from Yang et al. identify an atypical, clonally expanded population of activated Fc receptor-like 4 (FCRL4)+ B cells that is associated with improved overall survival in patients affected by various tumor types, including BRCA.
Journal
|
BRCA (Breast cancer early onset) • FCRL4 (Fc Receptor Like 4)
almost2years
Artificial intelligence and classification of mature lymphoid neoplasms. (PubMed, Explor Target Antitumor Ther)
In conclusion, although most categories are similar in both classifications, there are also conceptual differences and differences in the diagnostic criteria for some diseases. It is expected that AI will be incorporated into the lymphoma classification as another bioinformatics tool.
Review • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • CD79A (CD79a Molecule) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase) • MS4A1 (Membrane Spanning 4-Domains A1) • SOX11 (SRY-Box Transcription Factor 11) • FCRL4 (Fc Receptor Like 4)
2years
Molecular pathology assists the diagnosis of lymphoepithelial sialadenitis, Sjögren's syndrome and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. (PubMed, J Dent Sci)
FCRL4 B cells might play an important role in the formation of lymphoepithelial lesions and might be as a diagnostic positive marker of salivary MALT lymphoma. The application of multiple detection methods could significantly improve the diagnostic accuracy for MALT lymphomas from LESA and SS.
Journal
|
PAX5 (Paired Box 5) • FCRL4 (Fc Receptor Like 4)
almost3years
Nodal reactive proliferation of monocytoid B-cells may represent atypical memory B-cells. (PubMed, J Microbiol Immunol Infect)
Spatial transcriptomic analyses indicated that monocytoid cells may be atypical memory B-cells.
Journal • IO biomarker
|
PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • CDK6 (Cyclin-dependent kinase 6) • TBX21 (T-Box Transcription Factor 21) • CD40 (CD40 Molecule) • ITGAX (Integrin Subunit Alpha X) • FCRL4 (Fc Receptor Like 4)
almost3years
Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. (PubMed, Genome Med)
Neoadjuvant PD-1 blockade combined with chemotherapy led to distinct NSCLC tumor microenvironment transcriptomes that correlated with therapy response. Although limited by a small patient sample size subjected to combination therapy, this study provides novel biomarkers to predict therapy response and suggests potential strategies to overcome immunotherapy resistance.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • SPP1 (Secreted Phosphoprotein 1) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • FCRL4 (Fc Receptor Like 4)